Top Movers and Shakers Today

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  20 Oct 2025
 

•   ADAP  
   
  0.00%
•   ANRO  
   
  -1.69%
•   AQMS  
   
  -2.86%
•   BYND  
   
  +8.09%
•   CELC  
   
  -0.70%

$BYND is commanding attention this morning with a staggering 126% surge after the company announced a debt restructuring that appears to have pulled it back from the brink of bankruptcy. Beyond Meat stock jumped more than 24% immediately following Friday close and has continued its explosive rally as investors digest the implications of the debt swap arrangement. While the deal involves significant dilution for existing shareholders, the market is clearly relieved that the plant-based meat maker has secured a lifeline to continue operations. Trading volume has exploded to over 1 billion shares compared to its average of just 39 million, signaling intense interest from both retail and institutional traders. The stock now sits at $1.46, and while the dilution concerns are legitimate, the company has at least bought itself time to execute a turnaround strategy.

$REPL is another standout gainer, climbing nearly 98% in what appears to be momentum-driven trading activity. The stock has landed on the pre-market most active list alongside other high-volume names, suggesting that algorithmic trading and retail interest may be fueling the move. With volume surging to 106 million shares versus a typical 4.13 million daily average, this appears to be a classic case of a low-float stock catching fire on social media or trading platforms. The stock has rocketed to $8.90, though traders should exercise caution as these parabolic moves often reverse just as quickly as they develop.

$ANRO has posted an impressive 82% gain after Alto Neuroscience announced it secured $50 million in PIPE financing. This type of private investment in public equity demonstrates institutional confidence in the clinical-stage biotech prospects and provides crucial runway for advancing its neuroscience-focused pipeline. The stock is trading at $11.06 on volume of 17.15 million shares, well above its 2.3 million share average. For a small-cap biotech, this capital infusion removes near-term funding concerns and allows management to focus on clinical milestones rather than scrambling for cash.

$CELC stands out with a 37% gain driven by overwhelmingly positive Phase 3 data for gedatolisib in breast cancer treatment. Celcuity shares have not only surged on the clinical news but have also broken through the average analyst price target of $74.50, now trading at $70.58. When a biotech crosses analyst targets on positive data rather than hype, it typically signals genuine value creation. The volume spike to 6.49 million shares from a 1.07 million average underscores strong institutional accumulation. The Phase 3 success positions gedatolisib as a potentially transformative therapy in the breast cancer space, and investors are clearly betting on either partnership opportunities or eventual commercialization.

$IOBT rounds out the gainers with a 28% pop after revealing positive Phase 3 results for Cylembio in combination with Keytruda for advanced melanoma. IO Biotech cancer vaccine approach has now demonstrated clinical validation in a notoriously difficult-to-treat indication. The stock is trading at $0.85 on massive volume of 69.11 million shares compared to its usual 3.82 million. While the stock price remains under a dollar, which carries its own risks, the clinical data could attract partnership interest from larger oncology-focused pharma companies looking to expand their immuno-oncology portfolios.

On the downside,
$EXEL is getting hammered with a 13% decline after reporting mixed results from a cancer trial. Exelixis, typically a steady performer in the oncology space, is seeing its shares fall to $34.29 as investors parse through data that apparently fell short of expectations. The selloff is occurring on elevated volume of 7.63 million shares versus a 2.4 million average, suggesting institutional liquidation rather than just retail panic.

$AQMS has dropped 16% despite announcing a $13 million capital raise with a prominent institutional investor. Aqua Metals' sustainable lithium battery recycling technology hasn't been enough to prevent the dilution concerns from overwhelming any optimism about accelerated commercialization. The stock is at $12.22, and the muted volume of just 1.05 million shares against a 4.34 million average suggests investors are stepping aside rather than aggressively selling.

$OLMA has suffered a brutal five-day losing streak, now down another 16.5% to just $8. Olema Pharmaceuticals appears to be caught in a technical death spiral with no apparent catalyst to reverse the momentum. Volume has spiked to 4.85 million from 1.26 million average, indicating capitulation selling may be underway.

$UHG represents the day most dramatic collapse, plunging 53% after all but one director resigned from the board amid a leadership dispute. United Homes Group now trades at just $2 per share, and the governance crisis has sent volume surging to 4.76 million shares from a typical 90,000. Internal turmoil at the board level is rarely resolved quickly, and investors are fleeing en masse rather than waiting to see how this plays out.

$ADAP takes the crown for worst performer with a catastrophic 70% crash after Adaptimmune announced it will be delisting from NASDAQ. The stock has collapsed to just $0.06 on absolutely massive volume of 304 million shares compared to its 136.5 million average. A delisting typically signals either financial distress or a strategic decision to go private, but in either case, liquidity will evaporate for public shareholders and recovery prospects look virtually nonexistent at this point.

View All Headlines